ArticleClinical case reports2026
Delayed Recognition of Thrombotic Thrombocytopenic Purpura Following Platelet Transfusion: A Clinical Pitfall.
Article in Clinical case reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Thrombotic thrombocytopenic purpura (TTP) is a rare, life-threatening thrombotic microangiopathy caused by severe ADAMTS13 deficiency, usually due to autoantibody-mediated inhibition. Its presentation is heterogeneous and often lacks the classic pentad, leading to diagnostic delays. Neurological symptoms may predominate, masking the underlying hematologic emergency. In our case, a 37-year-old previously healthy woman presented with acute headache, speech disturbance, and altered mental status. Despite normal neuroimaging, laboratory tests revealed severe thrombocytopenia and normocytic anemia. Lack of response to erythrocyte and platelet transfusions prompted further evaluation, revealing microangiopathic hemolytic anemia with elevated lactate dehydrogenase, undetectable haptoglobin, indirect hyperbilirubinemia, reticulocytosis, and normal coagulation parameters. A PLASMIC score of 6/7 indicated a high probability of severe ADAMTS13 deficiency. Treatment with high-dose corticosteroids was initiated immediately, followed by plasma exchange and rituximab. ADAMTS13 activity confirmed severe deficiency at 0.3%, supporting the diagnosis of acquired TTP in the clinical context. The patient achieved rapid remission and complete neurological recovery. This case highlights the importance of early recognition of microangiopathic hemolysis and prompt treatment without waiting for confirmatory ADAMTS13 results to reduce morbidity and mortality.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.